Abstract:Background: Liver transplantation (LT) normalizes fasting tolerance in glycogen storage disease type (GSD) 1b. However, reported outcomes post-LT with respect to correction of neutropenia, infection risk and growth are varied. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been recently shown to improve neutropenia in GSD1b patients. Methods: In this single-center retrospective study, we reviewed all children who underwent LT for GSD1b. Neutropenia, dose of granulocyte colony-stimulating factor (G-CSF), unplanned hospital attendance, anthropometrics, graft rejection, survival, and the effects of dapagliflozin were analyzed. Data from protocol biopsies obtained at 1, 5, and 10 years post-LT and immunosuppression levels were collected. Results: Eight children (6 female), all on G-CSF pre-transplant, underwent cadaveric LT for GSD1b at median age 3.6 years (IQR 3.3-5.1) with mean follow-up time of 10.3 years (95% CI 7.5-13.1). Neutrophil count and G-CSF requirement did not improve post-LT. Although a reduction in unplanned hospital attendance due to infection (0.98 [95% CI 0.76-1.26] vs. 0.49 [95% CI 0.41 to 0.57] per person-year, p < 0.01) was observed, gastrointestinal complaints and graft dysfunction accounted for a similar hospitalization burden pre- versus post-LT. Body mass index (BMI) reduced post-LT (Z-score 1.47 [95%CI 0.39-2.23] vs. 0.56 [95% CI -0.74 to 1.45], p = 0.02), with no significant change in height. Although all children and grafts have survived, 75% of recipients developed rejection, despite adequate immunosuppression levels, with two children having been found to have developed significant fibrosis on their 5-year protocol biopsy. Although dapagliflozin allowed cessation of G-CSF, no improvement in neutrophil count was observed. Despite this, a reduction in gastrointestinal and infection-related morbidity was noted following dapagliflozin. Conclusion: Although LT normalizes fasting tolerance in GSD1b and reduces hospital attendance due to infection, morbidity from infection and gastrointestinal manifestations persist. Children in our cohort experienced high rates of rejection necessitating titration of immunosuppression to balance risk of infection against organ rejection. Future studies should investigate whether early introduction of SGLT2 inhibitors post-LT impact morbidity in this group.

Long‐Term Amino Acid Homeostasis, Neurodevelopmental and Growth Profiles Following Liver Transplantation in Maple Syrup Urine Disease

Safety and Long‐term Outcomes of Early Liver Transplantation for Pediatric Methylmalonic Acidemia Patients

Auxiliary Partial Orthotopic Liver Transplantation for Monogenic Metabolic Liver Diseases: Single-Centre Experience

Outcomes of Liver–kidney Transplantation in Patients with Primary Hyperoxaluria: an Analysis of the Scientific Registry of Transplant Recipients Database

Treatment Outcomes for Maple Syrup Urine Disease Detected by Newborn Screening

Liver Transplantation in Children with Urea Cycle Disorders: The Importance of Minimizing Waiting Time

The first case of domino‐split‐liver transplantation in maple syrup urine disease

Liver Transplantation for Propionic Acidemia and Methylmalonic Acidemia: Perioperative Management and Clinical Outcomes

Outcomes of Pediatric Liver Transplantation in Glycogen Storage Disease Type 1b-A Single-Center Experience

Expanding the genotypic and phenotypic spectrum of Egyptian children with maple syrup urine disease

Liver Transplantation Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Atypical Mevalonic Aciduria

Impact of citrulline substitution on clinical outcome after liver transplantation in carbamoyl phosphate synthetase 1 and ornithine transcarbamylase deficiency

Methylmalonic Acidemia/propionic Acidemia – the Biochemical Presentation and Comparing the Outcome Between Liver Transplantation Versus Non-Liver Transplantation Groups

Pediatric Liver Transplantation for Metabolic Liver Disease:Report of 42 Cases

The Impact of Diet on Body Composition in a Cohort of Pediatric and Adult Patients with Maple Syrup Urine Disease

An Early Diagnosis Leads to a Good Prognosis: a Patient with Maple Syrup Urine Disease--screened by Tandem Mass Spectrometry.

Metabolic Complications in Liver Transplantation Recipients: How We Can Optimize Long‐Term Survival

LIVER TRANSPLANTATION FOR THE TREATMENT OF CHILDREN WITH INHERITED METABOLIC LIVER DISEASES: SINGLE CENTER EXPERIENCE

Current status and future directions of liver transplantation for metabolic liver disease in children

Incidence of new-onset diabetes and posttransplant metabolic syndrome after liver transplantation - A prospective Study From South India

Impact of living donor liver transplantation on long-term cardiometabolic and graft outcomes in cirrhosis due to nonalcoholic steatohepatitis